To date, most of the prostate cancer-specific experience targeting this pathway comes from studies testing allosteric mTOR inhibitors, with these studies all generally failing to demonstrate sufficient activity to warrant further study [111–115]. The gene discussed is MTOR; the disease is prostate carcinoma.